{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-007283","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.672286+00:00","generated_at":"2026-05-15T17:52:13.193542+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pulse Biosciences reports 74% avg volume reduction in benign thyroid nodule ablation at 15-22 months","bullets":["21 patients monitored 15-22 months; average 74% volume reduction of benign thyroid nodules with no regrowth.","100% of patients highly satisfied with cosmetic appearance; 95% highly satisfied overall; no serious adverse events.","Data presented by Prof. Stefano Spiezia at North American Society for Interventional Thyroidology 2026 meeting.","CEO Paul LaViolette said non-cardiac nsPFA plans will be clarified in second half of 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-007283","json":"https://secwatch.observer/filing/0001437749-26-007283.json","markdown":"https://secwatch.observer/filing/0001437749-26-007283.md","text":"https://secwatch.observer/filing/0001437749-26-007283.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926007283/0001437749-26-007283-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926007283/plse20260306_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T17:52:13.193542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}